Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | USP10 | Q14694 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183832 | 0.90 | PDE10A (0.39) | PDE10ACHEK2CASRMAPTKDM4E | |
| SCHEMBL183833 | 0.90 | PDE10A (0.39) | PDE10ACHEK2CASRMAPTKDM4E | |
| SCHEMBL2603697 | 0.89 | CHEK2 (0.46) | PDE10ACHEK2CNR2MAPTKDM4E | |
| SCHEMBL2606242 | 0.89 | PDE10A (0.39) | PDE10ACHEK2CNR2MAPTKDM4E | |
| SCHEMBL183850 | 0.87 | CHEK2 (0.42) | CHEK2CASRMAPTKDM4EUSP10 | |
| SCHEMBL13157350 | 0.85 | DRD2 (0.41) | SSTR4CNR2MAPTKDM4ETP53 | |
| SCHEMBL13157356 | 0.85 | CNR1 (0.46) | CNR2MAPTKDM4ETP53USP10 | |
| SCHEMBL13157351 | 0.84 | DRD2 (0.36) | PDE10ACASRMAPTKDM4ETP53 | |
| SCHEMBL2603699 | 0.82 | CHEK2 (0.48) | PDE10ACHEK2CNR2MAPTKDM4E | |
| SCHEMBL2603709 | 0.82 | PRKDC (0.42) | PDE10ASSTR4CNR2OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8158637-B2 | Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158637-B2 | Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1957482-B1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | KCNQ1, KCNQ2, KCNQ5 | PDE10A 851/4885CHEK2 3091/4885SSTR4 4323/4885 |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | KCNQ1, KCNQ2, KCNQ5 | PDE10A 851/4885CHEK2 3091/4885SSTR4 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.